home azienda prodotti anatomia contatti
More info  

.: Riboflavin

Riboflavin (vitamin B2) is an heterocyclic compound obtained from a molecule of iso-allosazine to which it is bound to a ribitole chain.

Riboflavin is yellow in colour, scarcely soluble in water, remains stable under heat and becomes fluorescent under ultraviolet light.  When exposed to light, the photolysis reaction causes the detachment of the ribitole root and subsequent loss of the vitamin activity.

Riboflavin was first isolated in 1927 by Paul Gyorgy and in 1935 a synthesis was produced by Richard Kuhn. It can be found in many natural foods: beer yeast, offal, milk, albumen, fish, meat, green vegetables and is involved in many metabolic reactions, specially in human tissue.

lutein omega 3
basic Riboflavin 0,100 g
Destrane T500 15 g
Edetate sodium  
Bihydrate sodium phosphate monobasic  
Bihydrate sodium phosphate bibasic  
Purified water q.b. a 100 g

RICROLIN® TE- ophthalmic solution for cllagen cross-linking

RICROLIN®TE hypotonic ophthalmic solution containing Riboflavin (0.1%) and enhancers helping the Riboflavin pass through the intact corneal epithelium. The solution is used in the eye in conjunction with the administration of UV-A light, enabling cross-linking without the need to remove the corneal epithelium. The principal objective of RICROLIN®TE is to provide a barrier against UV-A penetration beneath the corneal stroma, and thus protect the delicate internal structures of the eye (corneal endothelium, lens and retina) from damage that may be caused by radiation. RICROLIN®TE solution is in fact capable of reducing up to 95% of the UV energy that reaches the deep strata of the cornea.
The transepithelial penetration of the Riboflavin, aided by the addition of enhancers and without the need to remove the corneal epithelium, facilitates cross-linking and cuts the time of the operation while reducing post-operative discomfort for the patient.


In association with ophthalmic UV-A radiation, the solution is administered during conservative procedures for keratoconus and other corneal estasia pathologies.
In particular the treatment is indicated in the following conditions:
• for all ectasic conditions of the cornea, whether genetic or iatrogenic
• for progressive keratoconus (clinically and instrumentally documented) and for diseases linked to wear of the cornea.
The treatment (UV-A + Riboflavin) helps to slow down the progression of keratoconus.
The treatment can prevent the necessity of corneal transplant.
The treatment does not exclude the possible need of keratoplasty in the future.

Instill 1 or 2 drops of RICROLIN®TE approximately every 2 minutes in the 30 minutes prior to the start of irradiation. During the application of UV-A, instill 1 or 2 drops of the product every 2-3 minutes throughout the operation (30 minutes in total).

There are no known contraindications associated with the ophthalmic solution.
Use must be avoided in cases of hypersensitivity reactions to the components of the
product or to otherchemically-related substances

No systemic or eye structure related side-effects have been reported

The product must be kept away from direct light.
Right up to the moment the product is to be utilised, it must be stored under refrigeration at a temperature between +4 and +8°C.
Kept within its dispenser, the solution is maintained sterile.
Do not touch the eye surface or other objects with the cannula needle in order to avoid the risk of contamination to the solution.
Do not utilise the product after more than one hour from first use.
Do not utilise the dispenser for more than one patient.
Do not utilise the product after the date indicated on the package.
Do not keep the product in temperature over 25°C.
The product is strictly indicated for external ophthalmic parasurgical use and is therefore utilised exclusively by registered Ophthalomologists.
Do not use if the package is damaged.

1 monodose sterile dispenser filled with 1 ml solution
1 sterile single-use cannula needle


flaguk end